# Bristol-Myers Squibb Company (BMY) — Q4-2021 Earnings Results

**Report date:** 2022-02-04 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q4-2021

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 1.44%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.83 | N/A | +0.11% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized the importance of their product pipeline and future growth potential.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite no revenue guidance.

> They highlighted ongoing commitment to innovation and pipeline development.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 1.44% increase. The lack of revenue data leaves some uncertainty, but management's focus on innovation suggests they are positioning for future growth. Investors may view the EPS beat as a sign of resilience in a challenging market.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q4-2021_